How would analogues/agonists interfere with thyroid and estradiol? They are being prescribed and used quite successfully in transgendered women.
J Clin Endocrinol Metab. 2012 Dec;97(12):4422-8. doi: 10.1210/jc.2012-2030. Epub 2012 Oct 9.
Predictive markers for mammoplasty and a comparison of side effect profiles in transwomen taking various hormonal regimens.
"Antiandrogens are not routinely used in the clinical protocol but GnRH analogs are routinely used to suppress testosterone production."
Exp Clin Endocrinol Diabetes. 2005 Dec;113(10):586-92.
Endocrine treatment of male-to-female transsexuals using gonadotropin-releasing hormone agonist.
"Sixty male-to-female transsexuals were treated with monthly injections of gonadotropin-releasing hormone agonist (GnRHa) and oral oestradiol-17beta valerate for 2 years to achieve feminisation until SRS. There was a significant decline in gonadotropins, total testosterone and calculated free testosterone. In general, the treatment regimen was well accepted. An equal increase in breast size was achieved compared to common hormone therapy. Two side effects were documented. One, venous thrombosis, occurred in a patient with a homozygous MTHFR mutation. One patient was found to be suffering from symptomatic preexisting gallstones. No other complications were documented. Liver enzymes, lipids, and prolactin levels were unchanged. Significantly increased oestradiol and SHBG serum levels were detectable. In addition, an increase in bone mass density, in the femoral neck and lumbar spine, was recorded. We conclude that cross-sex hormone treatment of male-to-female transsexuals using GnRHa and oestradiol-17beta valerate is effective, and side effects and complication rates can be reduced using the treatment regimen presented here."